Consistent absence of BRAF mutations in salivary gland carcinomas
Conclusions: According to our results SGCs didn’t acquire BRAF mutations that result in a constitutive activation of the signaling cascade downstream of EGFR, hence SGCs can be a good candidate for anti EGFR therapies.
Source: Journal of Dental Materials and Techniques - Category: Dentistry Source Type: research
More News: Adenocarcinoma | Adenoids | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Radiation Therapy | Study